ArticleACS omega2025
Photonic Crystal Microarray-Assisted Point-of-Care Testing for Rapid and Convenient Detection of Microalbuminuria.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) remains one of the most serious complications of type 2 diabetes, significantly impacting patients' morbidity and mortality. Microalbuminuria (mALB), a clinically validated biomarker, plays a key indicator for both early diagnosis and predicting the progression of DKD. However, existing point-of-care testing methods for albumin detection often suffer from limited sensitivity and operational complexity. To overcome these challenges, we developed and evaluated a fully printed, photonic crystal-integrated microarray-assisted point-of-care platform specifically designed for the rapid and precise detection of mALB. The system employs polymer latex microspheres, selected for their optical compatibility with detection fluorophores, as signal-enhancing carriers. By exploiting the photonic bandgap and photon localization effects inherent in photonic crystal structures, the platform significantly amplifies fluorescence signals in immunoassays, thereby substantially enhancing detection sensitivity and resolution. A detection method based on a double-antibody sandwich immunoassay was employed, enabling specific antigen-antibody binding and accurate quantification. Validation using clinical urine samples demonstrated the diagnostic efficiency of the platform. The full analysis can be executed in under 10 min, demonstrating a robust linear association between the fluorescence level and the mALB content.. The platform achieved a detection limit of 19.5 pg mL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.